Abeona Therapeutics Inc vs Anheuser-Busch Inbev SA — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Anheuser-Busch Inbev SA trades at $79.59 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 377.5× Abeona Therapeutics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BUD | |
|---|---|---|
Market Cap | $421.19M | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $86.48 |
52-Week Low | $4.17 | $57.93 |
Enterprise Value | $276.10M | $223.42B |
Dividend Yield | — | 1.67% |
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →